RNAZ Transcode Therapeutics Inc

Price (delayed)

$1.68

Market cap

$28.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$52.37

Enterprise value

$20.71M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on ...

Highlights
The EPS has soared by 88% YoY but it fell by 4.1% QoQ
Transcode Therapeutics's net income has plunged by 74% YoY and by 6% from the previous quarter
The quick ratio has plunged by 68% YoY and by 35% from the previous quarter

Key stats

What are the main financial stats of RNAZ

RNAZ stock price

How has the Transcode Therapeutics stock price performed over time
Intraday
-5.08%
1 week
0%
1 month
-41.46%
1 year
-83.94%
YTD
-75.4%
QTD
-72.95%

Financial performance

How have Transcode Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$45.13M
Net income
-$42.83M
Gross margin
N/A
Net margin
N/A
Transcode Therapeutics's net income has plunged by 74% YoY and by 6% from the previous quarter
The company's operating income fell by 6% QoQ

Price vs fundamentals

How does RNAZ's price correlate with its fundamentals

Growth

What is Transcode Therapeutics's growth rate over time

Valuation

What is Transcode Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 88% YoY but it fell by 4.1% QoQ

Efficiency

How efficient is Transcode Therapeutics business performance
The company's return on assets has surged by 87% YoY and by 26% QoQ

Dividends

What is RNAZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNAZ.

Financial health

How did Transcode Therapeutics financials performed over time
The quick ratio has plunged by 68% YoY and by 35% from the previous quarter
The current ratio has plunged by 63% YoY and by 37% from the previous quarter
Transcode Therapeutics's debt is 102% more than its equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.